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Abstract
Background: Early growth response-1 (Egr-1) is an immediate-early transcription factor inducible
in the vasculature in response to injury, shear stress, and other stimuli. Mice lacking Egr-1 have a
profound deficit in the ability to recover from femoral artery ligation, suggesting a role in
neovascularization. Previous studies have shown that manipulating Egr-1 expression can have either
positive or negative effects on tumor growth. We hypothesized that Egr-1 knockout mice might
exhibit reduced tumor growth, possibly due to a reduced capacity to respond to angiogenic signals
from a growing tumor.
Results: We injected 106 Lewis lung carcinoma (LLC1) cells subcutaneously in the flank of wild
type and Egr-1 knockout mice. The average mass of tumors from wild type mice at 12 days after
implantation was 413 +/- 128 mg, while those from Egr-1-/- mice was 219 +/- 81 mg (p = 0.001,
mean +/- SD). However, sectioning the tumors and staining with anti-CD31 antibodies revealed no
difference in the vascularity of the tumors and there was no difference in angiogenic growth factor
expression. Expression of the chemokine Mig (CXCL9) was increased 2.8-fold in tumors from
knockout mice, but no increase was found in serum levels of Mig. Natural killer cells have a 1.7-fold
greater prevalence in the CD45+ cells found in tumors from Egr-1-/- mice compared to those from
wild type mice. Immunohistochemical staining suggests that Mig expression in the tumors comes
from invading macrophages.
Conclusion:  Mice deficient in Egr-1 exhibit reduced growth of LLC1 tumors, and this
phenomenon is associated with overexpression of Mig locally within the tumor. There are no
obvious differences in tumor vascularity in the knockout mice. Natural killer cells accumulate in the
tumors grown in Egr-1-/- mice, providing a potential mechanism for the reduction in growth.
Background
Growth of a tumor can be significantly influenced by its
interactions with the surrounding stromal tissue.
Endothelial and immune system cells that invade the
tumor affect its rate of proliferation. Chemokines can act
to attract cells of the immune system to the site of tumor
growth. Monokine induced by interferon-γ (Mig) [1], also
known as CXCL9, is a chemokine that attracts T-cells and
natural killer (NK) cells [2]. Mig also has angiostatic prop-
erties [3]. Overexpression of Mig in tumors can lead to T-
cell accumulation, vascular damage, and tumor regression
[4,5].
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Egr-1 is a zinc-finger transcription factor that is inducible
by radiation [6], serum [7], shear stress [8], and other
stimuli in a variety of cell types, including tumor cells
[9,10]. Previous studies have examined the effects of
manipulating Egr-1 in tumors. Overexpression of Egr-1
delivered via adenovirus resulted in reduced tumor
growth and diminished expression of angiogenic factors
in a mouse model [11]. However, reduction of Egr-1 levels
through use of a DNAzyme also resulted in slower tumor
growth [12,13]. In some of these studies it was difficult to
clearly distinguish the effects of the delivered reagents on
tumor versus stromal tissue.
We have previously shown that Egr-1 knockout mice
exhibit a defect in arteriogenesis, as illustrated by their
greatly reduced capacity to recover hind limb blood flow
after femoral artery ligation [14]. We speculated that the
absence of Egr-1 in the stromal tissue of mice might have
an effect on tumor growth, possibly due to dysregulation
of angiogenic signalling. Our present work shows that
growth of at least some tumors is slowed in Egr-1 deficient
mice, but with no apparent effect on angiogenesis.
Instead, Mig accumulates in the tumor, along with NK
cells.
Results
Lewis lung carcinoma growth is slowed in Egr-1-/- mice
To assess the rate of tumor growth in Egr-1-/- mice, we
introduced 106 Lewis lung carcinoma cells (LLC1) subcu-
taneously in the flank of wild type and knockout animals.
After 12 days, we excised the tumors and weighed them.
Figure 1a shows that tumors from wild type mice are 1.9-
fold larger than those from knockout mice (p = 0.001).
Repeating this experiment using B16F10 melanoma cells
demonstrated no significant difference in the rate of
tumor growth between the two types of mice (Figure 1b),
as has been previously shown for this cell line [13].
Mig is overexpressed in LLC1 tumors from Egr-1-/- mice
In an attempt to elucidate molecular differences that
might underlie the reduced growth rate in LLC1 tumors,
we subjected tumor lysates to an antibody array. The array
allows analysis of 24 proteins related to blood vessel
growth. We found very little difference in expression pat-
terns between tumors grown in wild type and Egr-1-/-
mice, except that Mig was elevated by about 5.8-fold in
knockout-derived tumors, and IL-12p40/p70 was ele-
vated about 1.7-fold (Figure 2). Repeating the experiment
using lysates from B16F10 tumors failed to show any dif-
ferences in Mig or IL12p40/p70 expression (Figure 2).
To confirm the expression levels of Mig, we made addi-
tional lysates from LLC1 tumors grown for 11–12 days in
wild type and Egr-1-/- mice and measured Mig using a BD
cytometric bead array. Levels of Mig were 2.8-fold higher
in knockout-derived tumors (Figure 3a). To determine
whether this disparity represents a systemic difference in
Mig expression between the two types of mice, we also
measured Mig in serum from the same animals and found
no significant difference (Figure 3b). We attempted to
measure Mig in the tissue immediately underlying the
tumor (peritoneal wall and associated muscle), but the
levels were below the threshold of detection of our assay
(data not shown).
Mig is expressed in tumor macrophages in Egr-1-/- mice
Since the tumor Mig does not appear to be derived from
serum or surrounding tissue, we hypothesized that it was
being made in situ by some type of invading host-derived
Weight of tumors grown in wild type and knockout mice Figure 1
Weight of tumors grown in wild type and knockout 
mice. One million tumor cells were injected subcutaneously 
in wild type (WT) and Egr-1 knockout (KO) mice. Tumors 
were excised and weighed after 12 days. Averages and stand-
ard deviations are shown, with p values calculated by Stu-
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cell. We sectioned LLC1 tumors after 12 days of growth in
knockout mice and performed immunofluorescence
staining using antibodies against Mig. We found punctate
staining that colocalized with expression of CD68, which
is a marker for macrophages (Figure 4).
We attempted to measure Mig in resting monocytes iso-
lated from the spleens of wild type and Egr-1-/- mice using
a cytometric bead array, but the levels were below the
threshold of detection. Mig is known to be inducible in
monocyte/macrophages by interferon-γ (IFN-γ). We cul-
tured splenic monocytes with 100 ng/ml IFN-γ and meas-
ured Mig in the supernatant five hours later, but there was
no difference in the level of induction between wild type
and knockout monocytes (data not shown).
NK cell invasion of LLC1 tumors in Egr-1-/- mice is greater 
than in wild type
Mig is known to be chemotactic for T-cells and natural
killer (NK) cells [2]. We dissociated LLC1 tumors derived
from wild type and Egr-1-/- mice into single cell suspen-
sions and labelled them with fluorescently-tagged anti-
bodies against the T-cell receptor (CD3), leukocyte
common antigen (CD45), and NK1.1, a NK cell marker in
C57Bl/6 mice. We then counted the number of T-cells and
NK cells as a fraction of CD45+ cells in the tumors using
flow cytometry. Figure 5 (top panel) shows that there is a
significant increase in the percentage of NK cells in tumors
derived from knockout mice relative to those from wild
type mice. To assess whether the increased numbers of NK
cells in the tumors reflects a constitutive property of the
knockout mice, we counted cells in whole blood taken
from the same animals at the time of tumor harvest. There
was no significant difference. We similarly counted T-cells
in dissociated tumors and blood and found no significant
difference between the wild type and mutant mice (Figure
5, bottom panel). CD11b+ monocyte/macrophages are
also similar in number in tumors from the two types of
mice (data not shown).
Antibody array analysis of tumor lysates Figure 2
Antibody array analysis of tumor lysates. (Top) Schematic of the placement of antibodies on the array. Orange ellipses 
highlight the position of Mig. POS = positive control, NEG = negative control, bFGF = basic fibroblast growth factor, G-CSF = 
granulocyte colony stimulating factor (CSF), GM-CSF = granulocyte/macrophage CSF, IGF-II = insulin-like growth factor II, IL = 
interleukin, MCP-1 = monocyte chemoattractant protein-1, PF4 = platelet factor 4, TIMP = tissue inhibitor of metalloprotein-
ase, TNF = tumor necrosis factor, TPO = thrombopoietin, VEGF = vascular endothelial growth factor. (Bottom, left) arrays 
treated with LLC1 tumor lysates from wild type and knockout mice. (Bottom, right) arrays treated with B16F10 tumor lysates 
from wild type and knockout mice.Journal of Hematology & Oncology 2009, 2:7 http://www.jhoonline.org/content/2/1/7
Page 4 of 8
(page number not for citation purposes)
Capillary growth is normal in LLC1 tumors grown in Egr-1-
/- mice
There is evidence that Mig possesses angiostatic properties
[3]. We sectioned LLC1 tumors from wild type and Egr-1-
/- mice after 12 days of growth, stained for endothelial
cells (Figure 6a, b), and measured vascularity both by the
microvascular density method and the Chalkley method
[15]. There was no significant difference in the vascularity
by either approach (Figure 6c).
Discussion
Our work demonstrates that the growth of subcutaneous
LLC1 tumors in Egr-1-/- mice is impeded. This impediment
correlates with overexpression of Mig in the tumor, a phe-
nomenon that is not observed in B16F10 tumors, which
do not exhibit slower growth in Egr-1-/- mice. Mig has pre-
viously been shown to slow the growth of tumors in vari-
ous models. In a mouse model of Burkitt's lymphoma,
intra-tumoral injection of Mig protein results in partial
necrosis of the tumor [5]. Likewise, adenoviral delivery of
the Mig gene shrinks non-small cell lung carcinomas [16].
Walser, et al. [4], injected mice with mammary adenocar-
cinoma cells overexpressing Mig and found that these
cells formed smaller tumors than the parental cell line.
Our antibody array analysis (figure 2) examined expres-
sion of several genes potentially regulated by Egr-1,
including bFGF [17], TNF-α [18], IGF-II [19], and M-CSF
[20], but there was no significant alteration in expression
of these genes between groups.
CXCR3 serves as a receptor for Mig, as well as for related
chemokines IP-10 (CXCL10) [21] and I-TAC (CXCL11)
[22]. It is expressed on T-cells and NK cells. We were
somewhat surprised that there was not a greater degree of
T-cell infiltration in the tumors grown in Egr-1-/- mice, but
there may have been dysregulation of other chemokines
Confirmation of Mig expression Figure 3
Confirmation of Mig expression. Mig was measured 
using a cytometric bead array. Averages and standard devia-
tions are shown, with p values calculated using Student's t-
test. WT = wild type and KO = Egr-1 knockout source ani-
mal. (A) Mig in LLC1 tumor lysates, shown as picograms of 
Mig per microgram of protein. (B) Mig in serum from tumor-
bearing mice.
Colocalization of Mig and CD68 in LLC1 tumor sections Figure 4
Colocalization of Mig and CD68 in LLC1 tumor sections. (Left) Mig staining. (Middle) CD68 staining. (Right) Superposi-
tion of the left and middle photos.Journal of Hematology & Oncology 2009, 2:7 http://www.jhoonline.org/content/2/1/7
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that were not assayed on our antibody array, and these
may have influenced the degree of lymphocyte invasion
and activation. Also, our analysis looks at one time point,
and we cannot exclude the possibility T-cells may be
involved at earlier or later time points. While we cannot
conclude from our data that NK cells were responsible for
the slower tumor growth that we observed, others have
implicated NK cells in Mig-mediated tumor inhibition
[23] and have shown that NK cells recruited by Mig impair
metastasis [4]. Also, Wald, et al. [24] showed that growth
of Lewis lung carcinoma tumors is impaired in an NK cell-
dependent manner in response to IFN-γ, which stimulates
production of Mig.
The connection between the lack of Egr-1 and overexpres-
sion of Mig is unclear. We are not aware of any literature
suggesting that Egr-1 directly regulates Mig, or whether
other Egr family members play a role in its expression.
Mig is not produced in the tissue underlying the tumor,
nor is it systemically higher in the knockout mice, which
suggests that it is being produced in the tumor mass itself.
Since the injected tumor cells are identical in the two types
of animals, we hypothesized that Mig is produced from a
host-derived cell that invades the tumor, and our colocal-
ization experiment with a macrophage marker, CD68,
confirms this. Previous studies have shown that mono-
cyte/macrophages develop normally in Egr-1-/- mice [25],
and respond to stimulus with lipopolysaccharide simi-
larly to wild type monocytes [26]. We were unable to
detect any difference in the expression of Mig in mono-
cytes from knockout mice, but we cannot exclude the pos-
sibility that macrophages exposed to the tumor
environment may express Mig aberrantly.
Prevalence of natural killer (NK) and T-cells Figure 5
Prevalence of natural killer (NK) and T-cells. Cells were labelled and counted by flow cytometry as a percentage of 
CD45+ cells. Averages and standard deviations are shown, with p values calculated using Student's t-test. WT = wild type and 
KO = Egr-1 knockout source animal. (Top) NK cells in tumor and whole blood derived from tumor-bearing mice. (Bottom) T-
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We originally hypothesized that there might be a differ-
ence in blood vessel growth in the knockout mouse
tumors, based on our previous work showing a defect in
arteriogenesis in these animals [14]. However, the anti-
body array revealed no differences in expression of com-
mon angiogenic growth factors like VEGF and bFGF. Mig
is reported to have an angiostatic effect [3], and disrupted
blood vessel growth has been implicated as a factor in the
mechanism for Mig-mediated tumor shrinkage in some
studies [5,16]. But experiments with breast adenocarcino-
mas [4] and lung carcinomas [27] have failed to find
changes in angiogenesis in Mig-treated tumors. The
immunohistochemical staining we employed to measure
vascular density did not detect any difference in vascular-
ity, though we cannot rule out subtle effects on vessel
growth. Given that Egr-1 can potentially regulate expres-
sion of hundreds of genes [28], other factors may have
compensated for any angiostatic effects of Mig in our
model.
Both over- and under-expression of Egr-1 can impede
tumor growth. In a mouse fibrosarcoma model, anti-
tumor and anti-angiogenesis effects were observed in
response to injection of an adenovirus encoding Egr-1
[11], but the gene was delivered to both tumor and
stroma. Other researchers have shown that reducing Egr-1
Vascularity of tumor sections Figure 6
Vascularity of tumor sections. LLC1 tumors were sectioned and stained using anti-CD31 antibodies. (A) Section from 
tumor grown in wild type mouse. (B) Section from tumor grown in Egr-1-/- mouse. (C) Results of blinded counting of sections 
from three wild type (WT) and Egr-1 knockout (KO) tumors, using either the microvascular density method (MVD), i.e., 
counting all distinct vessels in a high power field, or the Chalkley method, i.e., placing a gridwork over the photograph and 
counting those vessels that touch the grid, as described [15]. Values shown are averages and standard deviations.Journal of Hematology & Oncology 2009, 2:7 http://www.jhoonline.org/content/2/1/7
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expression in human breast cancer cells can dampen their
growth and invasiveness [12]. Fahmy, et al. [13] used
DNAzymes to block expression of murine Egr-1 in nude
mice injected with the human breast cancer cell line MCF-
7. They found a reduced rate of tumor growth, which they
attributed to inhibition of angiogenesis. But since this
experiment was performed in athymic nude mice, the role
of the immune system is uncertain. Another study exam-
ined tumor development in mice genetically predisposed
to prostate cancer that had been crossed with Egr-1-/- mice.
This study showed a decreased progression of the tumor
from carcinoma in situ to invasive carcinoma, though ini-
tial growth rate and vascularity were unaffected [29].
Again, both tumor and stroma lacked Egr-1, making it dif-
ficult to assess the contribution of these two compart-
ments. Our work stands apart from these previous efforts
in that we have looked at the effect of eliminating Egr-1 in
the stroma alone using an immunocompetent animal.
Doing so has allowed us to uncover a previously unde-
scribed involvement of Egr-1 in Mig regulation and natu-
ral killer biology.
A limitation of our study is that our work does not tell us
whether Mig is the primary causative agent involved in the
reduction of tumor growth seen in the knockout mice.
The fact that the B16F10 tumors do not overexpress Mig
and also do not exhibit growth inhibition suggests that
Mig might be playing a role. The reason for the lack of Mig
expression in the B16F10 melanomas is unclear, but we
note that the antibody array shows a dramatic difference
between the two types of tumors in the expression of
monocyte chemoattractant protein-1 (MCP-1). In both
wild type and knockout mice, MCP-1 is absent in the
melanomas but is so abundant in the LLC1 tumors that it
saturates the array. We speculate that the lack of MCP-1
may affect monocyte activity in the B16F10 tumors, and
hence Mig expression, but we cannot exclude other poten-
tial differences between the two types of tumors.
Conclusion
We have shown that mice lacking Egr-1 have impaired
growth of LLC1 tumors, and that this correlates with
increased expression of Mig in the tumor. The Mig appears
to come from invading macrophages. Natural killer cells
accumulate to a greater extent in the LLC1 tumors of
knockout mice compared to those in wild types. There is
no obvious difference in vascularity between tumors
grown in the two types of mice. Unlike LLC1 cells, B16F10
melanomas exhibit no alteration in Mig or in tumor
growth in Egr-1-/-  mice, a finding that highlights the
importance of the choice of model system when examin-
ing tumor/stromal interactions.
Methods
Mice and tumor model
Egr-1 knockout mice were obtained from Taconic and
maintained on a C57Bl/6 background. Wild type C57Bl/6
mice were used as negative controls. All procedures were
approved by the Stony Brook University Institutional Ani-
mal Care and Use Committee. Lewis lung carcinoma cells
(LLC1) were obtained from ATCC (#CRL-1642) as were
B16F10 melanoma cells (#CRL-6475). Both cell lines
were maintained in Dulbecco's modified Eagle's medium
with 10% fetal bovine serum. One million cells were
injected subcutaneously in the flank in a volume of 50 μl
of saline. Cells were filtered through a 70 μm filter prior
to injection to remove any clumps.
Flow cytometry
Tumors were excised after 11–12 days of growth, weighed,
and digested in 470 units/ml collagenase II and 167 μg/
ml hyaluronidase in RPMI medium at 37° for 25 minutes.
Single cell suspensions were obtained by trituration and
the cells were labelled with antibodies against CD3 (eBio-
science, phycoerythrin-labelled), NK1.1 (eBioscience,
allophycocyanin-labelled) and CD45 (BioLegend, PerCP-
labelled) as described in the text. In some cases, cells were
also labelled with anti-CD11b antibodies (BioLegend,
Alexa Fluor 488-labelled). After fixation with 10% forma-
lin, cells were analyzed on a FACS Calibur (Becton, Dick-
inson). Blood cells were similarly measured in whole
blood obtained via cardiac puncture from tumor-bearing
mice at the time of euthanasia. Blood was cleared of eryth-
rocytes by lysis in ACK lysing buffer (BioWhittaker).
Expression assays
Lysates were made from powdered frozen tumors and
were subjected to analysis on a RayBiotech Mouse Angio-
genesis Antibody Array I using the manufacturer's rea-
gents and protocols. Mig levels were measured using a BD
Cytometric Bead Array (Becton, Dickinson) on tumor
lysates and on serum collected from tumor-bearing mice
at the time of euthanasia. Protein in the lysates was meas-
ured using the DC protein assay (Bio-Rad).
Monocyte culture
Mouse spleens were crushed and forced through a 70 μm
nylon filter and erythrocytes were lysed with ACK lysing
buffer. The resulting cells were labelled with anti-CD11b
antibodies (BioLegend, Alexa 488-labelled) and anti-Ly6c
antibodies (Southern Biotech, phycoerythrin-labelled).
Monocytes were sorted on a FACS Aria (Becton, Dickin-
son) and cultured in RPMI. IFN-γ was obtained from Ray-
Biotech.
Immunohistochemistry
Tumors were frozen in optimal cutting temperature
(OCT) medium, sectioned, fixed in methacarn, andJournal of Hematology & Oncology 2009, 2:7 http://www.jhoonline.org/content/2/1/7
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stained using Alexa 488-labelled anti-CD68 (Serotec) and
biotinylated anti-Mig (R&D Systems). The Mig staining
was achieved using a tyramide staining kit (Invitrogen).
Endothelial cells were stained on frozen sections using
biotinylated anti-CD31 (eBioscience) and tyramide stain-
ing. Endothelial cell counting was performed by a blinded
observer as described [15].
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